Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma

Cancer Journal (United States)

Volumn 18, Issue 5, 2012, Pages 450-456

  Foyil, Kelley V ^a   Bartlett, Nancy L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaplastic large cell lymphoma; anaplastic lymphoma kinase; brentuximab vedotin; crizotinib

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CRIZOTINIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; LYMPHOCYTE ANTIBODY; PRALATREXATE; PREDNISONE; ROMIDEPSIN; TOPOTECAN; VEDOTIN; VINBLASTINE; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIGEN EXPRESSION; BRAIN HEMORRHAGE; CANCER PROGNOSIS; CANCER RECURRENCE; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NAUSEA; NEUROBLASTOMA; NEUROTOXICITY; NEUTROPENIA; OCULAR FLASH; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSTATITIS; PROTEIN EXPRESSION; RARE DISEASE; RASH; RESPIRATORY FAILURE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL DISORDER; VOMITING;

CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; OLIGOPEPTIDES; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES;

EID: 84866940531     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31826aef4a     Document Type: Review

References (46)

1. Bartlett NL, YounesA, Carabasi MH, et al. A phse 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;114:1848-1854.
2. Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (antiCD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146:171-179.
3. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti- CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25:2764-2769.
4. Staber PB, Vesely P, Haq N, et al. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood. 2007;110:3374-3383.
5. Zarno A, Chiarle R, Piva R, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene. 2002;21:1038-1047.
6. Wellmann A, Doeesva V, ButscherW, et al. The activated anaplastic lymphoma kinase increases cell proliferation and oncogene up-regulation in rat 1a fibroblasts. FASEB J. 1997;11:965-972.
7. Singh RR, Cho-Vega JH, Davuluri Y, et al. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. Cancer Res. 2009;69:2550-2558.
8. Swerdlow SH, Camp E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
9. Savage KJ, Harris NL, Vose JM, et al. ALKY anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496-5504.
10. Schmitz N, Tumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116:3418-3425.
11. Sibon D, Fournier M, Briere J, et al. Prognostic factors and long term outcome of 138 adults with systemic anaplastic large-cell lymphoma: a retrospective study by the Groupe d'Etudes Des Lymphomes De l'Adulte (GELA). Blood. 2010;116. Abstract 322.
12. Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the MD Anderson Cancer Center experience. Cancer. 2005;103:2091-2098.
13. Gressin R, Peoch M, Deconinck E, et al. The VIP-ABVD regimen is not superior to the CHOP 21 for the treatment of non-epidermotropic peripheral T-cell lymphoma. Final results of the LTP95 protocol of the GOELAMS. Blood. 2006;108. Abstract 2464.
14. Glass B, Kloess M, Bentz M, et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive non-Hodgkin lymphoma. Blood. 2006;107:3058-3064.
15. Pfreundschuh M, Zwick C, Zeynalova S, et al. Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: II. Results of the randomized high-CHOEP trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2008;19:545-552.
16. Moccia AA, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines. Blood. 2009;114. Abstract 408.
17. Reimer P, Rüdinger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106-113.
18. Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19:958-963.
19. Corradini P, Dodero A, Zallio F. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol. 2004;22:2172-2176.
20. Le Gouill S, Milpied N, Buzyn A, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Grancaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol. 2008;26:2264-2271.
21. Zinzani PL, Magagnoli M, Bendandi M, et al. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients. Ann Oncol. 1998;9: 1351-1353.
22. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol. 2001;113:185-187.
23. Le DeleyMC, Rosolen A,Williams D, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;25: 3987-3993.
24. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631-636.
25. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182-1189.
26. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotech. 2003;21:778-784.
27. Francisco JA, Cerveny CG, Meyer D, et al. cAC1-vcMMAE, an anti- CD30-monomethyl auristain E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458-1465.
28. Okeley NM, Miyamoto JB, Zhang X, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res. 2010;16:888-897.
29. Cerveny CG, Law CL, McCormick RS, et al. Signaling via the anti- CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional therapeutics. Leukemia. 2005;19:1648-1655.
30. Oflazoglu E, Kissler KM, Sievers EL, et al. Combination of the anti- CD30-auristatin-E antibody-drug conjugated (SGN-25) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol. 2008;142:69-73.
31. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363: 1812-1821.
32. Fanale M, Forero-Torres A, Rosenblatt JD, et al. A phase 1 weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18: 248-255.
33. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190-2196.
34. Bartlett N, Brice P, Chen RW, et al. Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: a phase II study. J Clin Oncol. 2012;30. Abstract 8027.
35. Foyil KV, Kennedy DA, Grove LE, et al. Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma. Leuk Lymph. 2012;53:506-507.
36. Forero-Torres A, Berryman RB, Advani RH, et al. Prolonged treatment with brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). Blood. 2011;118. Abstract 3711.
37. Fanale M, Illidge T, Advani R, et al. Frontline therapy with brentuximab vedotin in patients with newly diagnosed systemic anaplastic large-cell lymphoma. Presented at the T-Cell Lymphoma Forum, San Francisco, CA; January 26-28, 2012.
38. Zou HY, LiW, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007;67: 4408-4417.
39. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363: 1693-1703.
40. Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALKpositive nonYsmall cell lung cancer (NSCLC). J Clin Oncol. 2011;29. Abstract 2501.
41. Riely GJ, Kim D, Crinò L, et al. Phase 2 data for crizotinib (PF-02341066) in ALK-positive advanced nonYsmall cell lung cancer (NSCLC): PROFILE 1005. J Thorac Oncol. 2011;6. Abstract O31.05.
42. Crinò L, Kim D, Riely GJ, et al. Initial phase II results with crizotinib in advanced ALK-positive nonYsmall cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol. 2011;29. Abstract 7514.
43. Mosse YP, Balis FM, Lim MS, et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children's Oncology Group phase I consortium study. J Clin Oncol. 2012;30. Abstract 9500.
44. Giambacorti-Passerini C, Pogliani EM. Crizotinib in anaplastic largecell lymphoma. N Engl J Med. 2011;364:775-776.
45. Pogliani EM, Dilda I, Villa F, et al. High response rate to crizotinib in advanced, chemoresistant ALK+ lymphoma patients. J Clin Oncol. 2011;29. Abstract e18507.
46. Wagner-Johnston ND, Bartlett NL, Cashen AF, et al. Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin [published online ahead of print April 23, 2012]. Leuk Lymph.